Live Breaking News & Updates on Capricor Therapeutics

Stay updated with breaking news from Capricor therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Capricor Advances in DMD Therapy With Positive Study Data

Capricor Advances in DMD Therapy With Positive Study Data
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Capricor Therapeutics ,

Analysts' Recent Ratings Updates for Capricor Therapeutics (CAPR)

Analysts' Recent Ratings Updates for Capricor Therapeutics (CAPR)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Citigroup Inc , Cantor Fitzgerald , Jump Financial , Vanguard Group Inc , Oppenheimer Holdings Inc , News Ratings For Capricor Therapeutics Inc Daily , Capricor Therapeutics Inc , Capricor Therapeutics , Therapeutics Stock Down , Therapeutics Inc , Get Free Report , Financial Markets , Capricor Therapeutics Inc Daily ,

Jump Financial LLC Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Jump Financial LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 52,800 shares of the biotechnology company’s stock, valued at approximately $258,000. Jump Financial LLC owned approximately 0.17% […] ....

Cantor Fitzgerald , Exchange Commission , Capricor Therapeutics Inc , Citigroup Inc , Jump Financial , Free Report , Capricor Therapeutics , Get Free Report , Capricor Therapeutics Daily ,

Capricor Therapeutics (NASDAQ:CAPR) Earns Outperform Rating from Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research report sent to investors on Friday, MarketBeat reports. The brokerage issued an outperform rating and a $14.00 price target on the biotechnology company’s stock. CAPR has been the topic of several other reports. StockNews.com lowered shares of Capricor Therapeutics from […] ....

Citigroup Inc , Jump Financial , Vanguard Group Inc , Capricor Therapeutics Inc , Cantor Fitzgerald , Capricor Therapeutics , Free Report , Moderate Buy , Get Free Report , Financial Markets , Vanguard Group , Capricor Therapeutics Daily ,

Capricor Therapeutics (NASDAQ:CAPR) Given New $25.00 Price Target at LADENBURG THALM/SH SH

Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its target price hoisted by LADENBURG THALM/SH SH from $24.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports. LADENBURG THALM/SH SH currently has a buy rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on CAPR. StockNews.com upgraded […] ....

Vanguard Group Inc , Jump Financial , Capricor Therapeutics Inc , Citigroup Inc , Capricor Therapeutics Company Profile , Cantor Fitzgerald , Capricor Therapeutics , Free Report , Moderate Buy , Get Free Report , Financial Markets , Vanguard Group , Capricor Therapeutics Daily ,